Kornimate/medical-research-clean huggingface dataset:
development of an educational video game to improve nursing students' reasoning with acute heart failure patients

Conditions: Heart Failure; Motivation

Summary: the aim of this study is to appreciate, using quantitative and qualitative empirical methods, the contribution of an educational video game to the engagement, the motivation, and the development of nursing students' interpretation of acute heart failure patients' health condition. two prototypes of the same educational video game have been developed. study participants will play with both prototypes, complete online questionnaires and be interviewed by a research assistant regarding their experience with both prototypes. study results will serve to select the most promising prototype between the two, based on its potential to support the engagement, the motivation, and the development of nursing students' interpretation of acute heart failure patients' health condition. study results will also serve to refine the selected prototype before conducting a larger-scale efficacy trial. as such and given the small sample number of participants that is expected, it is not planned to conduct hypothesis testing.


Eligibility criteria:
inclusion criteria: * as part of a bachelor of nursing program, to be registered in a course in which acute heart failure concepts are a focus. exclusion criteria: * no exclusion criteria

Keywords: clinical reasoning intrinsic motivation serious gaming nursing education undergraduate education
effect of probiotics on gut-liver axis of alcoholic hepatitis

Conditions: Alcoholic Liver Disease

Summary: background/aims: the investigators explored the therapeutic effects of probiotics in patients with ah. methods: between december 2012 and january 2015, the investigators conducted a 7-day, double-controlled, randomized, prospective clinical trial comparing the efficacy of probiotics in improving liver enzymes, lps, pro-inflammatory cytokines, stool culture, and stool polymerase chain reaction denaturing gradient gel electrophoresis. ah was defined as an aspartate aminotransferase (ast)/alanine aminotransferase (alt) \> 2 and elevated ast (alt) level with an alcohol consumption history within 48 hours. patients were randomized to receive 7 days of cultured lactobacillus rhamnosus r0011/acidophilus r0052 (120 mg/day) or placebo. the levels of liver enzymes, modified discriminant function (mdf), lps, and pro-inflammatory cytokines, stool culture, and stool polymerase chain reaction denaturing gradient gel electrophoresis were checked at baseline and again after therapy.

background/aims: alcoholic hepatitis (ah) is one of the leading causes of liver diseases. gut-derived microbial lipopolysaccharide (lps) has been known as a central role in the pathogenesis of ah. some animal studies suggested an emerging role of probiotics in restoration of the bowel flora and improving liver enzymes. we explored the therapeutic effects of probiotics in patients with ah. methods: between december 2012 and january 2015, the investigators conducted a 7-day, double-controlled, randomized, prospective clinical trial comparing the efficacy of probiotics in improving liver enzymes, lps, pro-inflammatory cytokines, stool culture, and stool polymerase chain reaction denaturing gradient gel electrophoresis. ah was defined as an aspartate aminotransferase (ast)/alanine aminotransferase (alt) \> 2 and elevated ast (alt) level with an alcohol consumption history within 48 hours. patients were randomized to receive 7 days of cultured lactobacillus rhamnosus r0011/acidophilus r0052 (120 mg/day) or placebo. the levels of liver enzymes, modified discriminant function (mdf), lps, and pro-inflammatory cytokines, stool culture, and stool polymerase chain reaction denaturing gradient gel electrophoresis were checked at baseline and again after therapy.

Eligibility criteria:
inclusion criteria: * alcoholic hepatitis (ast/alt \>2 \& elevated ast (alt) level * alcohol \>60 g/day (m), \>40 g/day (f) during 7 days before screening * last drinks: within 48 hours prior to admission) exclusion criteria: * viral hepatitis, * autoimmune hepatitis, * pancreatitis, * hemochromatosis, * wilson's disease, * drug-induced liver injury, * cancer, * infection need for antibiotics, * severe ah, or * obesity (bmi \>30 kg/m2)

Keywords: hepatitis probiotics lipopolysaccharides cytokines alcoholics
metformin hydrochloride in treating patients with pancreatic cancer that can be removed by surgery

Conditions: Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer

Summary: this randomized clinical trial studies metformin hydrochloride in treating patients with pancreatic cancer that can be removed by surgery. metformin hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

primary objectives: i. to determine the effect of escalating doses of metformin (metformin hydrochloride) given pre-operatively on pancreatic cancer cell proliferation and apoptosis. secondary objectives: i. to assess toxicity of escalating doses of metformin given pre-operatively in patients with resectable pancreatic carcinoma. ii. to measure the effect of metformin on the expression of phosphorylated acetyl-coa carboxylase alpha (acc), phosphorylated mechanistic target of rapamycin (serine/threonine kinase) (mtor), and pancreatic cancer stem cells. outline: patients are randomized to 1 of 3 treatment groups. group i: patients undergo observation. group ii: patients receive metformin hydrochloride orally (po) twice daily (bid) for at least 7 days in the absence of disease progression or unacceptable toxicity. group iii: patients receive metformin hydrochloride as in group ii. after completion of study treatment, patients are followed up 30 days.

Eligibility criteria:
inclusion criteria: * patients must have histologically or cytologically confirmed resectable pancreatic carcinoma; patients with pancreatic neuroendocrine tumors are not eligible * patients must be previously untreated with chemotherapy or radiation therapy * eastern cooperative oncology group (ecog) performance status =\< 2 * patients must have surgical resection of the pancreas planned, with enrollment at least 7 days prior to surgery; patients with surgery scheduled \> 15 days will not be excluded * hemoglobin (hg)a1c must be below 7% * total bilirubin less than 1.5 x institutional upper limit of normal * aspartate aminotransferase (ast) (serum glutamic oxaloacetic transaminase \[sgot\]) =\< 2.5 x institutional upper limit of normal * alanine aminotransferase (alt) (serum glutamate pyruvate transaminase \[sgpt\]) =\< 2.5 x institutional upper limit of normal * serum creatinine within normal institutional limits * alkaline phosphatase \< 1.5 x institutional upper limit of normal * subjects must have the ability to understand and be willing to provide written informed consent exclusion criteria: * history of metformin use in the previous 3 months * treatment with neoadjuvant chemotherapy or radiation therapy * history of allergic reactions attributed to metformin * patients with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * metabolic acidosis, acute or chronic, including ketoacidosis * metastatic disease
high-intensity aerobic interval training in testicular cancer survivors

Conditions: Cardiovascular Diseases; Testicular Neoplasms

Summary: this study evaluates the impact of a supervised 12-week high-intensity aerobic interval exercise program (versus a self-directed exercise usual care group) on traditional and novel cardiovascular disease risk factors and surrogate markers of cardiovascular- and overall-mortality in a population-based sample of testicular cancer survivors.


Eligibility criteria:
inclusion criteria: * histologically confirmed history of testicular cancer exclusion criteria: * not sufficiently ambulatory to complete the first two stages of the aerobic exercise test. * have a psychiatric condition which impairs their ability to perform the required volume and intensity of exercise. * have any uncontrolled cardiovascular condition (i.e. heart disease, hypertension, diabetes, arrhythmia). * report performing any weekly vigorous intensity aerobic exercise in the past month.

Keywords: high-intensity interval training vo2peak brachial flow-mediated dilation carotid-femoral pulse wave velocity carotid intima-media thickness carotid distensibility respiratory sinus arrhythmia
pattern of cardiac arrhythmia in patients with masld

Conditions: Cardiac Arrhythmia; Metabolic Dysfunction Associated Steatotic Liver Disease

Summary: study the relationship between patients with masld and cardiac arrhythmia that could be occur in thos patients

study the cardiac arrhythmia that could be occur in patients suffering form metabolic dysfunction -assocatied steatotic liver disease and risk factors of them

Eligibility criteria:
inclusion criteria: * patients aged 18years or older patients with metabolic dysfunction -assocatied steatotic liver disease exclusion criteria: * rhd structural heart diseases liver diseases other than masld
integrin α6-targeted spect imaging of breast cancer

Conditions: Breast Cancer

Summary: a novel radiotracer 99mtc-rwy targeting integrin α6 was developed, and the pilot first-in-human study for spect imaging of breast cancer was performed in seven healthy volunteers and two breast cancer patients to assess the safety and potential clinical applications of 99mtc-rwy.

integrin α6 associates with the survival and migration of breast cancer cells, which emerges as a predictor of reduced overall survival and worse prognosis. in this study, we developed an integrin α6-targeted radiotracer 99mtc-rwy for spect imaging of breast cancer. the safety, biodistribution and radiation dosimetry were studied in seven healthy volunteers, and the clinical potential of 99mtc-rwy was examined in two breast cancer patients. a single dose of 11.1 mbq/kg 99mtc-rwy was injected intravenously. visual and semiquantitative methods were used to assess the spect/ct images. the routine hematoxylin-eosin (he) staining and immunohistochemistry (ihc) staining were subsequently carried out to confirm the integrin α6 expression of tumors.

Eligibility criteria:
inclusion criteria: * healthy volunteers. * body mass index (bmi) at 19 to 25 \[body mass index = body weight (kg)/ height squared (m2)\]; * clinical laboratory tests (heart, liver, kidney, blood) indicators are in the normal range or abnormalities without clinical significance; * informed written consents were obtained from all 9 subjects before the procedure. * patients in suspicion of breast cancer by mammography or ultrasonography, and being able to provide basic information. exclution criteria: • the investigator judged that it is not suitable for clinical trials based on the overall situation of the volunteers and patients.

Keywords: breast cancer integrin α6 spect
evaluation of deployment capability and accuracy of an outside the scope (ots), detachable catheter system for ablation of peripheral lung lesions: an ex-vivo human lung model study

Conditions: Lung Cancer

Summary: a novel ots detachable probe system carried outside and along the flexible bronchoscope has been developed. using this novel system, the operator can deploy the probe in the target bronchus and lesion and completely detach the scope from the probe.

lung ablative therapies have growing interest in the treatment of early-stage primary lung cancer in surgical high-risk patients and as part of multimodal treatment in patients with large lesions or metastatic malignant disease in the lungs. endobronchial ablative strategies allow deliver y of these therapies through a natural orifice and minimally invasive approach, potentially improving safety and reducing related morbidity. application and deployment of this system allows the operator to have constant control of the airway, preventing life-threatening hemoptysis and other complications. we hypothesize that this novel detachable ots system can be successfully deployed in the peripheral parenchymal target with potential clinical applications in the near future.

Eligibility criteria:
inclusion criteria: * patients who follow surgery for the removal of diseased lungs before being submitted to a bilateral lung transplant. exclusion criteria: * none
a prospective cohort study of myasthenia gravis in china

Conditions: Myasthenia Gravis

Summary: the goal of this prospective cohort study is to investigate long-term therapeutic strategies for myasthenia gravis (mg) and identify potential biomarkers. the main questions it aims to answer are: 1. whether low-dose oral steroids may lead to a reduction in the recurrence rate among patients with mg. 2. to identify potential biomarkers that can predict disease progression and prognosis. this study recruits well-controlled patients with mg. based on patient preferences and considerations such as coexisting conditions (e.g., uncontrolled hypertension, diabetes, severe osteoporosis, obesity), the participants will be non-randomly divided into two groups: a maintenance steroid therapy group and a withdrawal group (withdraw all immunosuppresants). subsequently, these groups of patients will undergo long-term follow-up assessments.


Eligibility criteria:
inclusion criteria: * 1: attended the outpatient department of neurology of pumch from 9/30/2022 to 9/30/2024. * 2: diagnosed as myasthenia gravis. * 3: follow-up time at pumch\>6 months. * 4: the patient understood and signed the informed consent form. exclusion criteria: * 1: comorbidities with other conditions that cause skeletal muscle weakness make the clinical symptoms difficult to assess * 2: records related to comorbidities and medications were not available at baseline and during follow-up.
community health workers and precision medicine

Conditions: Cancer; Tumor

Summary: the purpose of this randomized controlled trial is to evaluate whether a trained community health worker (chw) who engages with newly diagnosed patients after a diagnosis of cancer can effectively improve knowledge and receipt of evidence-based precision medicine cancer care services among low-income and minority patients.

the goal of this study is to reduce cancer disparities by improving the knowledge and delivery of evidence-based precision medicine for cancer care. we plan to randomize newly diagnosed patients and those currently under cancer care to either a control arm (usual cancer care alone) versus an intervention arm (layered on top of usual cancer care alone) where patients are assigned to a community health worker who will assist patients in ensuring the following discussions with their care team: 1) precision cancer care 2) cancer diagnosis and treatment plan 2) adherence to treatments and 3) goals of care and symptom burden. a total of 55 participants per study group (total 110) will be recruited in monterey county from pacific cancer care.

Eligibility criteria:
inclusion criteria: * newly diagnosed patients with a cancer diagnosis. * patients with any relapse or progressive disease (any cancer diagnosis) as identified by imaging or biopsy and confirmed by a physician. * the patients must be 18 years or older. * patients must have the capacity to verbally consent in english or spanish. * patients must be racial/ethnic minorities or low-income status or public insurance (medi-cal or other) or have health insurance provided by an agricultural company or be uninsured exclusion criteria: * patients under 18 years of age. * inability to consent to the study due to lack of capacity as documented by the referring physician. * patients without a newly diagnosed malignancy or patients without relapse of disease.

Keywords: precision medicine cancer care lay health worker community health worker cancer treatment patient satisfaction palliative care cancer diagnosis quality of care tumor testing end-of-life
maintaining independence and quality of life in aging adults through targeted cognitive training

Conditions: Mild Cognitive Impairment

Summary: mild cognitive impairment, alzheimer's disease and parkinson's disease all represent a range of degenerative conditions that have cognitive impairments which all limit the ability for older individuals to self-manage care, participate in daily activities and community participation. the consequences of these progressive diseases increase the requirement for residential care, associated medical costs and may negatively impact the overall quality of life and mental health for individuals. according to the alzheimer society of canada, over the next few decades, more than 1 million canadian's will be living with decreased cognitive ability and will require an increased amount of support, whether through family or institutional sources. currently, there are few cognitive programs for individuals diagnosed with mild cognitive impairment or for individuals wishing to maintain their current level of cognitive ability which translates to meaningful improvements in daily living and independence, as well as generalized intelligence. to date, the watson centre society for brain health (wcsbh) has successfully improved cognitive capacity, executive function and quality of life for over 100 individuals following a wide range of brain injury, and currently has a 77% return to work rate following completion of the full program. the program includes a combination of physical exercise, cognitive training and mindfulness meditation. the purpose of the research study is to explore the impact of an interdisciplinary cognitive rehabilitation program has upon the cognitive functioning and quality of life for individuals who are assessed to have mild cognitive impairment (mci). in particular, the aims of this study include: 1) to evaluate changes in cognition and quality life in older adults with mci. 2) to explore the potential for intensive cognitive intervention in slowing cognitive degeneration in older adults with mci.


Eligibility criteria:
inclusion criteria: * t-moca score between 19 - 23 exclusion criteria: * potential participants are under the age of 65 years at the time of screening * scoring results in a range outside of 19-23 on the moca * those who have have a diagnosed illness or diagnosed injury which is known to directly and negatively impact cognition * are known (legally) to be deemed incapable; unable to appreciate information that is relevant to making decisions or is unable to appreciate the reasonably foreseeable consequences of either making or not making a decision.
effects of health education for patients received minimally invasive lumbar spinal surgery

Conditions: Low Back Pain; Lumbar Degenerative Disease

Summary: lumbar degenerative disease surgery has been a routine clinical operation, and has good treatment effects. although the patient's neurological symptoms improve after surgery, many patients still have postoperative muscle soreness. the postoperative rehabilitation intervention for the patients receiving traditional lumbar surgery has been confirmed to effectively improve pain and disability. however, in recent years, minimally invasive lumbar spinal surgery has gradually replaced traditional surgery, postoperative pain has been greatly reduced. therefore, patients have the opportunity to receive early intervention in rehabilitation, but there is no standardization process for rehabilitation of minimally invasive lumbar spine surgery. therefore, this study aims to establish a health education program for patients receiving minimally invasive lumbar spinal surgery, and conduct clinical trials to test its effectiveness.


Eligibility criteria:
inclusion criteria: * age between 45 and 90 years old. * low back pain has been persisting at least 3 months. * clinical degeneration diagnosis supports the need of mi-tlif. * able to understand chinese. exclusion criteria: * emergency surgery. * unstable vital sign. * any psychological, neurological, orthopedics, cardiopulmonary, and cancer history. * had spinal surgery before. * pregnancy.

Keywords: rehabilitation lumbar degenerative disease low back pain
real-world experience on the use of upadacitinib in the treatment of moderate-severe adult atopic dermatitis (eruda)

Conditions: Atopic Dermatitis

Summary: real-world experience on the use of upadacitinib in the treatment of adult moderate-severe atopic dermatitis

atopic dermatitis (da) is a chronic-recurrent inflammatory skin disease with high prevalence in children. clinical remission is frequently observed during or after childhood although it may persist and/or recur, even after long and transient remission, in adulthood. in addition, in some patients the da begins in adulthood: in these cases, we speak of da adult-onset. in addition to the diagnostic framework, it is also important in clinical practice to assess the severity of the disease on which the choice of treatment is based, which will also take into account other factors such as: possible comorbidities, previously performed therapies and patient needs. for the management of moderate-severe forms of atopic dermatitis topical drugs, phototherapy, traditional immunomodulating drugs and a biological drug are currently available. compared to other chronic inflammatory skin diseases the therapeutic paraphernalia should be considered limited, with most systemic drugs that have no indication for the treatment of da (off-label use). in the pipeline there are numerous drugs that have reached an advanced stage of development. these include upadacitinib, a new-generation oral drug (small molecule) that selectively inhibits the signal mediated by janus kinases 1 (jak-1), has recently received approval for treatment of da by ema and aifa to begin compassionate use of patients deemed contraindicated, intolerant, and/or non-responsive to traditional systemic therapies and biological therapy. * evaluation of the effectiveness of upadacitinib using the easi score secondary objectives * evaluation of the safety profile of upadacitinib * predictive factors of treatment response * assessment of patient quality of life

Eligibility criteria:
inclusion criteria: 1. age 18 years 2. signature of informed consent 3. diagnosis of moderate and/or severe da by a dermatologist specialist 4. approval of the compassionate use of upadacitinib exclusion criteria: 1. patient unable to give informed consent prior to any collection procedure study data 2. unable to complete the procedures required for the study